Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Two-Drug combo slashes bad cholesterol in High-Risk heart patients

NCT ID NCT05761444

First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 30 times

Summary

This study tested whether adding ezetimibe to the standard cholesterol drug atorvastatin helps very high-risk heart disease patients lower their LDL (bad) cholesterol more effectively. 137 adults with advanced heart disease participated. Results showed that the combination therapy led to greater LDL reductions and helped more patients reach their cholesterol goals compared to atorvastatin alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Chonnam National University Hospital

    Gwangju, Jeollanam-do, 61469, South Korea

  • Eunpyeong St. Mary's Hospital

    Seoul, Eunpyeong-gu, 03312, South Korea

  • Inje University Ilsan-Paik Hospital

    Goyang-si, Gyeonggi-do, 10380, South Korea

  • Kangbuk Samsung Hospital

    Seoul, 03181, South Korea

  • Keimyung University Dongsan Medical Center

    Daegu, Gyeongsangbuk-do, 42601, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, 13620, South Korea

  • Ulsan University Hospital

    Ulsan, Gyeongsangnam-do, 44033, South Korea

Conditions

Explore the condition pages connected to this study.